Conflicts of interest remain a widespread problem on FDA advisory committees, occurring in 15 to more than 70 percent of meetings among voting members.[1] Financial conflicts of interest, particularly consulting fees, research funding, and stock ownership, are very common among committee members and public speakers, with 25 percent of public speakers disclosing financial conflicts of interest.[1] While the evidence on the influence of voting members' conflicts of interest on decision-making is mixed, public speakers with financial conflicts of interest were consistently more likely to give favorable testimony, with odds ratios ranging from 3.0 to 6.1.[1] Studies suggest a decrease in the prevalence of conflicts of interest among members following the 2007 FDA Act, but a similar trend has not emerged among public speakers.[1] The researchers concluded that stronger and more consistent conflict of interest disclosure and management policies, including public speakers, are needed to protect decision-making integrity.[1]